On October 17, 2022 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT (Press release, Nuvalent, OCT 17, 2022, https://www.prnewswire.com/news-releases/nuvalent-to-host-conference-call-to-discuss-preliminary-phase-1-data-from-arros-1-clinical-trial-of-nvl-520-and-additional-preclinical-updates-in-conjunction-with-34th-eortc-nci-aacr-symposium-301650281.html [SID1234622085]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will be accessible through the "Events" section of the Investors page of www.nuvalent.com or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.